Partnering can go different ways

AOP Orphan is focusing on three different ways of partnering:

  • In-licensing
    AOP Orphan is a partner for pharmaceutical companies that develop or already have developed their product for the European market and want to reach patients in AOP Orphan’s core markets.
  • Out-licensing
    AOP Orphan is a licensor for in-house developments that will be distributed by partners in other countries.
  • Development Cooperation
    AOP Orphan is a partner in joint development projects.

In all cases, a trusting collaboration is based on:

  • being on an equal footing,
  • being a reliable partner,
  • having expertise and
  • sharing a passion for the project at hand.

Partnering is focused on the key treatment areas of:

  • Cardiology & Pulmonology,
  • Haemato-Oncology, and
  • Neurology & Metabolic Disorders.

In addition to these, AOP Orphan is open for further treatments in the field of rare diseases as well as specialty products. The complexity of the treatment areas requires long-term cooperation with all stakeholders in the healthcare system. For this reason, partnering is usually designed to continue for an extended period of time beyond the product life cycle.

Partner Stories: Successful together

For AOP Orphan, partnering can go both ways – as a partner for pharmaceutical companies that wish to place their product in AOP Orphan’s core markets, or as a licensor for in-house developments that will be distributed by partners in other countries. In both cases, a trusting win-win collaboration of reliable partner, having expertise and a passion for the project at hand.

Dr. Jean-Guillaume Lecomte Chief Executive Officer, Bioprojet Pharma SAS

"With Wakix® (pitolisant) we address a significant unmet medical need in the treatment of narcolepsy. Next to introducing Wakix in Western Europe with its own commercial organizations, Bioprojet is glad to expand Wakix access to narcolepsy patients and their physicians all over Northern and Central Eastern Europe with the support of AOP Orphan."

"AOP Orphan represents our products in various European countries with remarkable success. Our collaboration is highly professional and very efficient. AOP Orphan understands that partnering need to be win-win in order to be successful."

Lisa Bright President of Intercept International

"We are delighted that this new therapeutic option for PBC, the first in nearly 20 years in some regions, can be available in countries where Intercept is yet to have a commercial presence. This collaboration with AOP Orphan represents another step towards our mission of providing worldwide access to this new alternative treatment to improve the lives of those with PBC."

Dr. Harald Jainta Director Business Development, DESITIN ARZNEIMITTEL LTD

"We have been a partner of AOP Orphan for decades in distribution arrangements crossing products from AOP Orphan for Germany and brands from Desitin for Austria. AOP Orphan is a proven partner that works tirelessly to get transactions completed. Moreover, recent innovations of AOP Orphan have transformed us from a niche player into a smart development entity."

Dr. Philipp Novak Managing Director, orphanix GmbH

„In a modern complex and challenging pharmaceutical industry it is crucially important to cooperate with agile, reliable and efficient partners. Undoubtfully AOP Orphan is such partner for us. Mutual respect and a hands-on work attitude are a driving force in our joint vision: improving the lives of patients with rare diseases."

Dr. Michael Caballero Managing Director, Orpha Swiss

"Being one of our preferred partners since the day OrPha Swiss GmbH was founded, AOP and our collaboration played a crucial role in the success and build-up of our small Swiss niche pharma company. Now, after 14 years of collaboration, AOP Orphan has proven to be not only a reliable and professional business partner but also an innovator and problem-solver in the pharmaceutical niche and orphan drug sector."